APPEL A CANDIDATURES CHERCHEURS PERMANENTS IGF
Les équipes de l'IGF lancent un appel à candidatures pour accueillir des chercheurs permanents / titulaires au sein de leur groupe. Vous trouverez ci-dessous une description des équipes IGF qui accueillent des chercheurs permanents / titulaires.
Les candidats peuvent prendre contact directement avec les chefs d'équipes concernés. Pour les candidats intéressés par une autre équipe de l'IGF , ils faut prendre contact avec le Directeur d'Unité, Jean-Philipe PIN :
Our team is studying the development of GABAergic cerebellar circuit. Our main objective is to understand how neurons achieve synaptic specificity during neural circuit formation.
GABAergic inhibitory circuits consist of an array of interneuron cell types with distinct morphology, physiological properties, and synaptic connectivity patterns, and may constitute a scaffold to organize local cortical connectivity and activity. Indeed, one of the most puzzling feature of GABAergic interneurons is their specific subcellular domains innervation (i.e; soma, spines, dendrite and axon hillock) of their target neurons which allowed strong and precise control of synaptic input, integration and output patterns. Although GABAergic connectivity is essential for the construction of functional circuits, the formation and development of exquisite GABAergic circuits, including migration, axon guidance and synaptogenesis, in general are poorly characterized. The laboratory used several mice genetic model and original experimental approaches to decipher the cellular and molecular mechanisms involved in GABAergic circuit assembly.
We are seeking a highly-motivated researcher that want to join our team to investigate the mechanism of local GABAergic circuit formation in cerebellar cortex.
Link to Ango's team
Cyclin D1 is an oncogene that activates the CDK4 kinase and both genes are frequently altered across human malignancies. Since the discovery of CDK4 inhibitors against cancer, the scope of Cyclin D1 action has been widely investigated and its biological impact appears to go far beyond the regulation of CDK4 during cell cycle. In this frame, our team has contributed to demonstrate the importance of Cyclin D1 in transcriptional regulation and more recently in apoptosis.
Since 2016, strong of new patented tools to detect and modulate this protein, we gear our research efforts toward the development of novel clinical strategies based on RNA interference, to overcome deregulations of Cyclin D1 in cancer, but also in male infertility, cardiac ischemia and Parkinson disease, where we found unexpectedly Cyclin D1 to be implicated in the biology of post-mitotic quiescent cells. In vitro and in vivo, our results open a large field of research opportunities or therapeutic innovations to be exploited.
We now look forward to welcoming motivated collaborators to join our team efforts and strengthen our work force, to foster the translational research policy we initiated with the CNRS and the local industrial network relay (SATT AxLR).
In a dynamic research campus Arnaud de Villeneuve, the IGF provides excellent technological facilities in genomics, pharmacology and proteomics for the daily use of modern biology tools that are instrumental in our ambitious endeavor.
Link to Bienvenu's team
Our teams main objective is to identify genes which regulate myocardial regeneration in zebrafish and subsequently test these in mammals.
To determine suitable target genes, we use the substantial microarray data generated from studying heart regeneration in zebrafish. To further refine the selection of candidates from the microarray data, we target genes that are associated with specific processes that we have identified as being important for zebrafish heart regeneration. Once candidates have been selected and confirmed in our zebrafish model system we will begin testing these in vitro in mammalian cardiomyocytes before determining whether they are capable of inducing myocardial regeneration following cardiac ischemia in mammals.
Our other main line of research involves understanding the genetic regulation of heart development. In particular we utilize rapid embryonic zebrafish assays to quickly identify genes which are responsible for causing congenital heart defects in humans.
No prior experience is required although a willingness to learn new techniques/model system is essential.
Link to Jopling's team
Our goal is to establish a unique research approach positioning cerebrovascular dysfunctions at the crossroad of brain diseases and neuropharmacology. Building from a neuro-centric approach, we have confirmed the concept of the neuro-vascular unit and its implication in the pathophysiology of epilepsy and Alzheimer’s disease, which we now wish to expand to other brain pathologies (traumatic brain injury, neoplasms, ischemia, etc.). A network of Medical Doctors participates in our translational research projects, including neurologists from local, National and European Hospitals.
Our collaborations expand to the United States, where N. Marchi spent 10 years before arriving to Montpellier in 2013. Our research is currently funded by French (ANR, FFRE, FRC) and US (NIH, CURE) agencies, is established at the International level (60 publications; Scopus h-index = 29; citations 2013-2015 = 957) and presented at International meetings.